Jack Schjelderup1, Sigrun Hope2,3, Christian Vatshelle4, Clara D M van Karnebeek5,6. 1. Department of Habilitation for adults, Haukeland University Hospital, Bergen, Norway. 2. Department of Neurohabilitation, Oslo University Hospital, Oslo, Norway. 3. NORMENT, KG Jebsen Centre for Psychosis Research, University of Oslo, Oslo, Norway. 4. Strusshamn Legesenter, Askøy, Norway. 5. Department of Pediatrics, Amsterdam University Medical Centres, Amsterdam, the Netherlands. 6. Dept of Pediatrics - Metabolic diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Abstract
BACKGROUND: Creatine transporter deficiency (CTD) is an X-linked form of intellectual disability (ID) caused by SCL6A8 mutations. Limited information exists on the adult course of CTD, and there are no treatment studies in adults. METHODS: We report two half-brothers with CTD, 36 and 31 years at intervention start. Their clinical phenotypes were consistent with CTD, and intervention was indicated because of progressive disease course, with increased difficulties speaking, walking and eating, resulting in fatigue, and malnutrition. We therefore performed treatment trials with arginine, glycine and a proprietary product containing creatine and betaine, and then a trial supplementing with betaine alone. RESULTS: In the older patient, glycine and arginine were accompanied by adverse effects, while betaine containing proprietary product gave improved balance, speech and feeding. When supplementation stopped, his condition deteriorated, and improved again after starting betaine supplement. Betaine supplementation was also beneficial in the younger patient, reducing his exhaustion, feeding difficulties and weight loss, making him able to resume his protected work. DISCUSSION & CONCLUSION: We report for the first time that betaine supplement was well tolerated and efficient in adults with CTD, while arginine and/or glycine were accompanied by side effects. Thus, betaine is potentially a new useful treatment for CTD patients. We discuss possible underlying treatment mechanisms. Betaine has been reported to have antagonistic effect on NKCC1 channels, a mechanism shared with bumetanide, a medication with promising results in both in autism and epilepsy. Further studies of betaine's effects in well-designed studies are warranted.
BACKGROUND: Creatine transporter deficiency (CTD) is an X-linked form of intellectual disability (ID) caused by SCL6A8 mutations. Limited information exists on the adult course of CTD, and there are no treatment studies in adults. METHODS: We report two half-brothers with CTD, 36 and 31 years at intervention start. Their clinical phenotypes were consistent with CTD, and intervention was indicated because of progressive disease course, with increased difficulties speaking, walking and eating, resulting in fatigue, and malnutrition. We therefore performed treatment trials with arginine, glycine and a proprietary product containing creatine and betaine, and then a trial supplementing with betaine alone. RESULTS: In the older patient, glycine and arginine were accompanied by adverse effects, while betaine containing proprietary product gave improved balance, speech and feeding. When supplementation stopped, his condition deteriorated, and improved again after starting betaine supplement. Betaine supplementation was also beneficial in the younger patient, reducing his exhaustion, feeding difficulties and weight loss, making him able to resume his protected work. DISCUSSION & CONCLUSION: We report for the first time that betaine supplement was well tolerated and efficient in adults with CTD, while arginine and/or glycine were accompanied by side effects. Thus, betaine is potentially a new useful treatment for CTD patients. We discuss possible underlying treatment mechanisms. Betaine has been reported to have antagonistic effect on NKCC1 channels, a mechanism shared with bumetanide, a medication with promising results in both in autism and epilepsy. Further studies of betaine's effects in well-designed studies are warranted.
Authors: Reza Yaghmai; Amir H Kashani; Michael T Geraghty; Jay Okoh; Martin Pomper; Albert Tangerman; Conrad Wagner; Sally P Stabler; Robert H Allen; S Harvey Mudd; Nancy Braverman Journal: Am J Med Genet Date: 2002-02-15
Authors: A Sempere; C Fons; A Arias; P Rodríguez-Pombo; R Colomer; B Merinero; P Alcaide; A Capdevila; A Ribes; R Artuch; J Campistol Journal: J Inherit Metab Dis Date: 2009-03-25 Impact factor: 4.982
Authors: Elsa Ghirardini; Francesco Calugi; Giulia Sagona; Federica Di Vetta; Martina Palma; Roberta Battini; Giovanni Cioni; Tommaso Pizzorusso; Laura Baroncelli Journal: Genes (Basel) Date: 2021-07-24 Impact factor: 4.096